ICRA upgrades drug companies as China reopens
Posted by
www.biotecnika.org
When Icra revised the rating earlier this year, the fear was that a
shutdown in China prompted by the Covid-19 pandemic would block key
active pharmaceutical ingredients (APIs) from coming into the country.
APIs are the basic ingredients for drugs.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/icra-upgrades-drug-companies-as-china-reopens/articleshow/75497695.cms
Subscribe to:
Post Comments (Atom)
Post a Comment